Mixed
GLP-1 medicines for obesity are predominantly tested in white/Caucasian populations (79%) with significant under-representation of non-white, Black, Asian, and Indigenous groups compared to their prevalence in multiethnic national populations.
Current GLP-1 obesity trials heavily feature white participants (79%). If you belong to a racial or ethnic minority, be aware that the standard dosing and efficacy data may not fully reflect your specific physiological response or risk profile. Advocating for or seeking out diverse clinical data is important for personalized care.
Meta-analyses of prevalence demonstrated the vast predominance of white/Caucasians (79%) with smaller proportion of blacks (9%), Asians (13%), Indigenous (2%) and Hispanics (22%).
Why this rating
Systematic review and meta-analysis of 27 RCTs with 21,547 participants.
Source
Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps
Yaanu Jeyakumar et al. · BMJ Global Health · 2024
DOI 10.1136/bmjgh-2024-017177
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →